Hands OsteoarthritisPhase 4NCT02102620
Corticosteroid Intra-articular Injection in Hands Osteoarthritis
A Phase 4 study testing Intra-articular injection with corticosteroid and Intra-articular injection with lidocaine in people with Hands Osteoarthritis, run by Federal University of São Paulo at 1 site in Brazil.
Trial summary
Objective - to evaluate the effectiveness and tolerance of intra-articular injections (IAI) of hexacetonide triamcinolone (HT) for the treatment of osteoarthritis (OA) in interphalangeal joints. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Hands Osteoarthritis
- What is being tested?
- Intra-articular injection with corticosteroid and Intra-articular injection with lidocaine
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteBrazil
- Study dates
- Aug 2011to Jun 2013
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hand OA
- Age over 40
- Visual analogic scale (VAS) for pain at rest between 3-8cm
- Signed informed consent term
Who cannot join
- Change in the use of oral corticosteroid or nonsteroidal antiinflammatory (NSAID) in the last 30 days
- Change in drugs for OA in the last two months
- IAI in this joints in the last three months
- Any change in treatment for OA in the hands in the last two months
- Suspicion of local and or systemic infection, and pregnancy
- Hands X-ray suggesting arthropathy of the interphalanges of other etiology
- Serious coagulation disorder
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients
Objective - to evaluate the effectiveness and tolerance of intra-articular injections (IAI) of hexacetonide triamcinolone (HT) for the treatment of osteoarthritis (OA) in interphalangeal joints.
Design:randomized, controlled, double-blinded study Materials and methods: sixty patients were randomized into: the TH / lidocaine (LD) group (n=30) who underwent IAI at the most symptomatic interphalangeal joint with HT (20mg/ml) and LD 2% or the LD group (n=30) who received IAI with just LD. Patients were assessed at baseline, 1, 4, 8 and 12 weeks by a blinded observer. The following parameters regarding the affected joint were assessed: pain at rest (VASr); pain at movement (VASm); pain (VAS) during the 48 hours after the procedure; swelling (VASs); goniometry; grip and pinch strength; hand function; treatment improvement; daily requirement of paracetamol and incidence and types of local side effects after the procedure.
Read the detailed description
Background The aim of this study was to evaluate the effectiveness and tolerance of medium-term IAI of corticosteroids HT for the treatment of OA in proximal interphalangeal joints(PIP) or distal interphalangeal joints(DIP) joints on clinical and functional parameters.
Studies evaluating the effectiveness of intra-articular therapies in patients with hands OA are very heterogeneous, either by addressing different types of joints at the same time, for wearing unusual drugs, for failing to placebo groups , by using very soluble corticosteroid or not using corticosteroids.
Design A randomized, prospective, controlled, double-blinded, intention to treat study was performed.
Sample Patients were collected from the outpatient clinics of the Federal University of Sao Paulo, from August 2011 to August 2012. A total of 60 patients were randomized into two groups of 30 patients.
The patients had to fulfill the following inclusion criteria: diagnosis of PIP or DIP hands OA according to the American College of Rheumatology criteria, age greater than 40 years, and pain in at least one PIP or DIP hand joints between 3-8 cm on Visual Analog Scale for pain (VAS for pain at rest 0-10cm).
Patients with change in the corticosteroids or nonsteroidal antiinflammatory drug in the last thirty days; change in chondroprotective drugs in the last two months; IAI with corticosteroids in the studied joint in the last three months; any change in hand OA treatment in the last two months (rehabilitation, acupuncture and others); suspicion of local or systemic infection; hand x-ray suggesting another etiology of hand arthropathy (psoriatic arthritis, microcrystalline arthropathy, deposit disease) and severe coagulation disorder.
Intervention Patients were randomized into two groups. The study group was called hexacetonide triamcinolone / lidocaine (TH / LD) and a control group, called lidocaine (LD).
Patients in TH / LD group underwent treatment scheme in its most symptomatic interphalangeal (IP) joint composed of IAI with HT (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of HT for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) for both groups. Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
The procedures of the two groups were performed blindly by the same rheumatologist with 10 years of experience in interventional rheumatology after rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect 14 (Figure 1). After the procedure, the injected joint was immobilized for 48 hours, in both groups.
Assessment All patients had their data reported in an evaluation form. The data collected were: age, sex, race, use of chondroprotective drugs, anti-inflammatory and / or analgesics drugs. Hands x-ray was performed in anteroposterior view for study inclusion. The measurement was done according to the method of Kellgren and Lawrence and used to evaluate homogeneity of the sample.
Five assessment evaluations were scheduled for a total of 12 weeks of follow-up. Patients were assessed at T0 (before intervention), T1, T4, T8 and T12 weeks after intervention. The assessment was carried out by a "blinded" assessor, trained in assessment instruments. This study was an intention to treat study. The last observation carried forward in case of discontinuation.
Clinical assessment
The following parameters were assessed in both groups:
- Visual analogue scale (VAS) for rest pain (VASr 0- 10cm);
- VAS for movement pain (VASm 0- 10cm);
- VAS for joint swelling (VASs 0- 10cm);
- Joint goniometry in flexion (degrees of range of motion);
- Analgesic consumption after the intervention (paracetamol daily average);
- Grip strength using Jamar® dynamometer (kgf) by obtaining the average of three attempts;
- Pinch strength using dynamometer Pinch Gauge (kgf) - by obtaining the average of three trials for the three types of pinches: tip, key and tripod 16;
- Hand function assessed by COCHIN questionnaire and the AUSCAN Index using the sub-scales pain, stiffness and hand function;
- Treatment improvement scale varying 5 points (much worse, worse , unchanged, little improvement and much improved);
- Side effects following the procedure (atrophy and / or cutaneous hypochromia and joint instability);
- Worsening of pain after IAI measured by VAS (post IAI VAS 0- 10cm) in 48 hours after the procedure (reported only at T1) in both groups.
Sample Size Using the VAS for pain as the primary study variable, considering a standard deviation equal to 1.5 points, based on previous work , and using the ANOVA for repeated measures as the statistical method for the calculation of the sample, with power of 90%, 5% significance and a detectable difference of 2.0 points on the VAS pain scale, measured 5 times over time into two independent groups, the investigators found a sample of 24 patients for each group. Considering a possible loss of up to 20% of patients over time, the investigators started the study with 30 patients in each group.
Randomization Patients were randomized using the MINITAB 14.0 software, with secret allocation guaranteed by opaque sealed envelopes. The responsible for the inclusion of these patients had no prior access to randomization list; it was responsible for verifying that the patient was within the inclusion and exclusion criteria of the study and after this procedure refer patients to the evaluators in another room, where medication was prepared.
Sample Blinding Only the responsible for the inclusion / exclusion of patients had access to which group the patient belonged, after enrollment. Evaluators and the responsible for the procedure had no access to such information. This blinding was relative impaired, since the volume used in the infiltration group TH / LD was substantially greater than that used in the LD group. However the responsible for the procedure was not responsible for the recruitment/allocation or evaluation of the sample. Regarding this essay the evaluators did not identify problems related to "blinding" during the study.
Statistical methods SPSS software version 17.0 (Chicago, IL) was used to perform statistical analysis. The descriptive statistics (mean, standard deviation, confidence interval 95%) was used to characterize the patients in groups. Continuous variables of the 2 groups at baseline were compared using the Student t test (for normally distributed variables) and the Mann-Whitney test (for variables with distribution not considered normal). Categorical variables were evaluated using the chi-square test.
To assess the response to intervention, analysis of variance (ANOVA) with repeated measures was used to intragroup and intergroup analysis over time.
This study was considered statistically significant if p values <0.05.
- Conditions
- Hands Osteoarthritis
- Being tested
- Intra-articular injection with corticosteroid, Intra-articular injection with lidocaine
- Keywords
- intra-articular injection, corticosteroid, osteoarthritis, Interphalangeal joint
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intra-articular injection with corticosteroidDrug
Also called triancil
After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
Intra-articular injection with lidocaineDrug
Also called Xylestesin
After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
| Study group | Role | What they receive |
|---|---|---|
| IAI triamcinolone hexacetonide | Experimental | Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).
Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day). Receives: Drug: Intra-articular injection with corticosteroid |
| IAI lidocaine | Placebo comparator | Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion. Receives: Drug: Intra-articular injection with lidocaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in Pain Score on the Visual Analogue Scale (VAS) at 3 months
To evaluate the improvement on pain measure by:VAS for rest pain (VASr 0- 10cm) and movement (VASm 0- 10cm) in each time
Measured: 0 -1-4-8 and 12 weeks
Secondary outcomes (1)
Safety at 3 months
Side effects following the procedure (atrophy and / or cutaneous hypochromia and joint instability);
Measured: 0-1-4-8 and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2014 (estimated)
- Study startAug 2011
- Primary completionAug 2012
- Study completionJun 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hands OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Federal University of São Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Natalia de Oliva Spolidoro Paschoal, Federal University of São Paulo
- Investigators
- Natalia O Spolidoro Paschoal, Principal investigator, Federal University of São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02102620
- Sponsor's protocol ID
- FUSaoPauloRheum01
- Status last verified
- Mar 2014
- First submitted
- 24 Mar 2014
- Last updated
- 3 Apr 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Spolidoro Paschoal Nde O, Natour J, Machado FS, de Oliveira HA, Furtado RN. Effectiveness of Triamcinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Controlled Trial in Patients with Hand Osteoarthritis. J Rheumatol. 2015 Oct;42(10):1869-77. doi: 10.3899/jrheum.140736. Epub 2015 Aug 1.
PubMed 26233501
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients
- ClinicalTrials.gov ID
- NCT02102620
- Acronym / sponsor ID
- FUSaoPauloRheum01
- Conditions
- Hands Osteoarthritis
- Keywords
- intra-articular injection, corticosteroid, osteoarthritis, Interphalangeal joint
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Federal University of São PauloUniversity, hospital or other
- Study start
- Aug 2011
- Primary completion
- Aug 2012 (actual)
- Study completion
- Jun 2013 (actual)
- First posted
- 3 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective - to evaluate the effectiveness and tolerance of intra-articular injections (IAI) of hexacetonide triamcinolone (HT) for the treatment of osteoarthritis (OA) in interphalangeal joints.
Design:randomized, controlled, double-blinded study Materials and methods: sixty patients were randomized into: the TH / lidocaine (LD) group (n=30) who underwent IAI at the most symptomatic interphalangeal joint with HT (20mg/ml) and LD 2% or the LD group (n=30) who received IAI with just LD. Patients were assessed at baseline, 1, 4, 8 and 12 weeks by a blinded observer. The following parameters regarding the affected joint were assessed: pain at rest (VASr); pain at movement (VASm); pain (VAS) during the 48 hours after the procedure; swelling (VASs); goniometry; grip and pinch strength; hand function; treatment improvement; daily requirement of paracetamol and incidence and types of local side effects after the procedure.
Detailed description
Background The aim of this study was to evaluate the effectiveness and tolerance of medium-term IAI of corticosteroids HT for the treatment of OA in proximal interphalangeal joints(PIP) or distal interphalangeal joints(DIP) joints on clinical and functional parameters.
Studies evaluating the effectiveness of intra-articular therapies in patients with hands OA are very heterogeneous, either by addressing different types of joints at the same time, for wearing unusual drugs, for failing to placebo groups , by using very soluble corticosteroid or not using corticosteroids.
Design A randomized, prospective, controlled, double-blinded, intention to treat study was performed.
Sample Patients were collected from the outpatient clinics of the Federal University of Sao Paulo, from August 2011 to August 2012. A total of 60 patients were randomized into two groups of 30 patients.
The patients had to fulfill the following inclusion criteria: diagnosis of PIP or DIP hands OA according to the American College of Rheumatology criteria, age greater than 40 years, and pain in at least one PIP or DIP hand joints between 3-8 cm on Visual Analog Scale for pain (VAS for pain at rest 0-10cm).
Patients with change in the corticosteroids or nonsteroidal antiinflammatory drug in the last thirty days; change in chondroprotective drugs in the last two months; IAI with corticosteroids in the studied joint in the last three months; any change in hand OA treatment in the last two months (rehabilitation, acupuncture and others); suspicion of local or systemic infection; hand x-ray suggesting another etiology of hand arthropathy (psoriatic arthritis, microcrystalline arthropathy, deposit disease) and severe coagulation disorder.
Intervention Patients were randomized into two groups. The study group was called hexacetonide triamcinolone / lidocaine (TH / LD) and a control group, called lidocaine (LD).
Patients in TH / LD group underwent treatment scheme in its most symptomatic interphalangeal (IP) joint composed of IAI with HT (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of HT for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) for both groups. Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
The procedures of the two groups were performed blindly by the same rheumatologist with 10 years of experience in interventional rheumatology after rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect 14 (Figure 1). After the procedure, the injected joint was immobilized for 48 hours, in both groups.
Assessment All patients had their data reported in an evaluation form. The data collected were: age, sex, race, use of chondroprotective drugs, anti-inflammatory and / or analgesics drugs. Hands x-ray was performed in anteroposterior view for study inclusion. The measurement was done according to the method of Kellgren and Lawrence and used to evaluate homogeneity of the sample.
Five assessment evaluations were scheduled for a total of 12 weeks of follow-up. Patients were assessed at T0 (before intervention), T1, T4, T8 and T12 weeks after intervention. The assessment was carried out by a "blinded" assessor, trained in assessment instruments. This study was an intention to treat study. The last observation carried forward in case of discontinuation.
Clinical assessment
The following parameters were assessed in both groups:
- Visual analogue scale (VAS) for rest pain (VASr 0- 10cm);
- VAS for movement pain (VASm 0- 10cm);
- VAS for joint swelling (VASs 0- 10cm);
- Joint goniometry in flexion (degrees of range of motion);
- Analgesic consumption after the intervention (paracetamol daily average);
- Grip strength using Jamar® dynamometer (kgf) by obtaining the average of three attempts;
- Pinch strength using dynamometer Pinch Gauge (kgf) - by obtaining the average of three trials for the three types of pinches: tip, key and tripod 16;
- Hand function assessed by COCHIN questionnaire and the AUSCAN Index using the sub-scales pain, stiffness and hand function;
- Treatment improvement scale varying 5 points (much worse, worse , unchanged, little improvement and much improved);
- Side effects following the procedure (atrophy and / or cutaneous hypochromia and joint instability);
- Worsening of pain after IAI measured by VAS (post IAI VAS 0- 10cm) in 48 hours after the procedure (reported only at T1) in both groups.
Sample Size Using the VAS for pain as the primary study variable, considering a standard deviation equal to 1.5 points, based on previous work , and using the ANOVA for repeated measures as the statistical method for the calculation of the sample, with power of 90%, 5% significance and a detectable difference of 2.0 points on the VAS pain scale, measured 5 times over time into two independent groups, the investigators found a sample of 24 patients for each group. Considering a possible loss of up to 20% of patients over time, the investigators started the study with 30 patients in each group.
Randomization Patients were randomized using the MINITAB 14.0 software, with secret allocation guaranteed by opaque sealed envelopes. The responsible for the inclusion of these patients had no prior access to randomization list; it was responsible for verifying that the patient was within the inclusion and exclusion criteria of the study and after this procedure refer patients to the evaluators in another room, where medication was prepared.
Sample Blinding Only the responsible for the inclusion / exclusion of patients had access to which group the patient belonged, after enrollment. Evaluators and the responsible for the procedure had no access to such information. This blinding was relative impaired, since the volume used in the infiltration group TH / LD was substantially greater than that used in the LD group. However the responsible for the procedure was not responsible for the recruitment/allocation or evaluation of the sample. Regarding this essay the evaluators did not identify problems related to "blinding" during the study.
Statistical methods SPSS software version 17.0 (Chicago, IL) was used to perform statistical analysis. The descriptive statistics (mean, standard deviation, confidence interval 95%) was used to characterize the patients in groups. Continuous variables of the 2 groups at baseline were compared using the Student t test (for normally distributed variables) and the Mann-Whitney test (for variables with distribution not considered normal). Categorical variables were evaluated using the chi-square test.
To assess the response to intervention, analysis of variance (ANOVA) with repeated measures was used to intragroup and intergroup analysis over time.
This study was considered statistically significant if p values <0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| IAI triamcinolone hexacetonide | Experimental | Drug: Intra-articular injection with corticosteroidIntra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD). Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day). |
| IAI lidocaine | Placebo comparator | Drug: Intra-articular injection with lidocaineIntra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Hand OA
- Age over 40
- Visual analogic scale (VAS) for pain at rest between 3-8cm
- Signed informed consent term
Key exclusion criteria (7 listed)
- Change in the use of oral corticosteroid or nonsteroidal antiinflammatory (NSAID) in the last 30 days
- Change in drugs for OA in the last two months
- IAI in this joints in the last three months
- Any change in treatment for OA in the hands in the last two months
- Suspicion of local and or systemic infection, and pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intra-articular injection with corticosteroidAlso: triancilAfter rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours. | Drug | IAI triamcinolone hexacetonide |
| Intra-articular injection with lidocaineAlso: XylestesinAfter rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours. | Drug | IAI lidocaine |
Primary outcome
Change from baseline in Pain Score on the Visual Analogue Scale (VAS) at 3 months
Time frame: 0 -1-4-8 and 12 weeks
To evaluate the improvement on pain measure by:VAS for rest pain (VASr 0- 10cm) and movement (VASm 0- 10cm) in each time
1 secondary outcome
Safety at 3 months
Time frame: 0-1-4-8 and 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2014.
- Derived from this study: PubMed 26233501Spolidoro Paschoal Nde O, Natour J, Machado FS, de Oliveira HA, Furtado RN. Effectiveness of Triamcinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Controlled Trial in Patients with Hand Osteoarthritis. J Rheumatol. 2015 Oct;42(10):1869-77. doi: 10.3899/jrheum.140736. Epub 2015 Aug 1.
Related trials for Hands Osteoarthritis
Active, not recruiting
Balneotherapy in Hand Osteoarthritis
Hand Osteoarthritis
Active, not recruitingPhase 4
Methotrexate in Erosive Inflammatory Hand Osteoarthritis
Hand Osteoarthritis, Erosive Osteoarthritis
Recruiting
Surgery for Thumb Base Osteoarthritis: Joint Replacement vs. Trapeziectomy
Thumb Osteoarthritis, Thumb Carpometacarpal Joint Osteoarthritis
Active, not recruitingPhase 2
Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis
Osteoarthritis Hand
RecruitingPhase 2/3
Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments
Erosive Hand Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natalia O Spolidoro Paschoal principal investigator
Federal University of São Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Intra-articular injection with corticosteroid and Intra-articular injection with lidocaine in people with Hands Osteoarthritis, run by Federal University of São Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in Pain Score on the Visual Analogue Scale (VAS) at 3 months (time frame: 0 -1-4-8 and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02102620, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2014.